| pubmed-article:2854245 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2854245 | lifeskim:mentions | umls-concept:C1882598 | lld:lifeskim |
| pubmed-article:2854245 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2854245 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:2854245 | lifeskim:mentions | umls-concept:C0058901 | lld:lifeskim |
| pubmed-article:2854245 | lifeskim:mentions | umls-concept:C0122180 | lld:lifeskim |
| pubmed-article:2854245 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2854245 | pubmed:dateCreated | 1989-5-26 | lld:pubmed |
| pubmed-article:2854245 | pubmed:abstractText | The ACTH4-9-analog Hoe 427 systemically injected in a dose range from 0.01-10 micrograms/kg caused a fall in acetylcholine (ACh) content in different brain areas of the rat. This effect occurred 0.5 hour after a single administration and lasted up to 24 hours. The decrease in ACh content induced by Hoe 427 was more pronounced when the animals were pretreated with dexamethasone (over 7 days 1 mg/kg SC, daily). Coadministration of the choline uptake inhibitor hemicholinium-3 (HC-3) and Hoe 427 potentiated the decrease in ACh content induced by HC-3. In the same dose range Hoe 427 acutely evoked an increase of the activity of the enzyme choline acetyltransferase as well as an elevation of brain cyclic GMP content. These data indicate that Hoe 427 enhances ACh metabolism in rat brain after systemic administration. | lld:pubmed |
| pubmed-article:2854245 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2854245 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2854245 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2854245 | pubmed:issn | 0196-9781 | lld:pubmed |
| pubmed-article:2854245 | pubmed:author | pubmed-author:GeigerRR | lld:pubmed |
| pubmed-article:2854245 | pubmed:author | pubmed-author:Von... | lld:pubmed |
| pubmed-article:2854245 | pubmed:author | pubmed-author:GerhardsH JHJ | lld:pubmed |
| pubmed-article:2854245 | pubmed:author | pubmed-author:WiemerGG | lld:pubmed |
| pubmed-article:2854245 | pubmed:author | pubmed-author:HockF JFJ | lld:pubmed |
| pubmed-article:2854245 | pubmed:author | pubmed-author:UsingerPP | lld:pubmed |
| pubmed-article:2854245 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2854245 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:2854245 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2854245 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2854245 | pubmed:pagination | 1081-7 | lld:pubmed |
| pubmed-article:2854245 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:meshHeading | pubmed-meshheading:2854245-... | lld:pubmed |
| pubmed-article:2854245 | pubmed:articleTitle | Neurochemical effects of the synthetic ACTH4-9-analog Hoe 427 (Ebiratide) in rat brain. | lld:pubmed |
| pubmed-article:2854245 | pubmed:affiliation | HOECHST AG, Frankfurt/M, FRG. | lld:pubmed |
| pubmed-article:2854245 | pubmed:publicationType | Journal Article | lld:pubmed |
